Document is current
Any future updates will be listed below
-
Authors
Sciacovelli, Marco
Dugourd, Aurelien
Jimenez, Lorea Valcarcel https://orcid.org/0000-0002-7309-9924
Yang, Ming
Nikitopoulou, Efterpi
Costa, Ana S. H. https://orcid.org/0000-0001-8932-6370
Tronci, Laura
Caraffini, Veronica
Rodrigues, Paulo
Schmidt, Christina
Ryan, Dylan Gerard https://orcid.org/0000-0003-4553-9192
Young, Timothy
Zecchini, Vincent R.
Rossi, Sabrina H. https://orcid.org/0000-0001-7048-7158
Massie, Charlie https://orcid.org/0000-0003-2314-4843
Lohoff, Caroline
Masid, Maria https://orcid.org/0000-0001-6470-5083
Hatzimanikatis, Vassily https://orcid.org/0000-0001-6432-4694
Kuppe, Christoph https://orcid.org/0000-0003-4597-9833
Von Kriegsheim, Alex
Kramann, Rafael
Gnanapragasam, Vincent https://orcid.org/0000-0003-4722-4207
Warren, Anne Y.
Stewart, Grant D. https://orcid.org/0000-0003-3188-9140
Erez, Ayelet https://orcid.org/0000-0002-9696-0393
Vanharanta, Sakari https://orcid.org/0000-0001-5619-7963
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
Frezza, Christian https://orcid.org/0000-0002-3293-7397
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MRC_MC_UU_12022/6)
Cancer Research UK (C51061/A27453)
- License Information
-
More Information
Article History
Received: 20 October 2021
Accepted: 16 November 2022
First Online: 20 December 2022
Competing interests
: G.D.S. has received educational grants from Pfizer, AstraZeneca, and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma, and CMR Surgical; Travel expenses from Pfizer and Speaker fees from Pfizer. J.S.R. reports funding from GSK and Sanofi, and consultant fees from Travere Therapeutics and Astex Pharmaceutical. The remaining authors declare no competing interests.
